Department of Gastroenterology, Komaki City Hospital, Komaki, Japan.
Hepatol Res. 2015 Jan;45(2):238-46. doi: 10.1111/hepr.12331. Epub 2014 Apr 24.
Hepatocellular carcinoma develops even in some patients who achieve a sustained virological response following treatment for hepatitis C virus infection. This study investigated the relationship between changes in fibrosis, as assessed by sequential biopsies, and development of hepatocellular carcinoma in patients who achieved a sustained virological response for hepatitis C virus.
We enrolled 97 patients with sustained virological response who had undergone initial biopsies before therapy and sequential biopsies at an average of 5.8 ± 1.9 years after the initial biopsy. Factors associated with hepatocellular carcinoma were retrospectively analyzed.
The liver fibrotic stage regressed in 44 patients (45%), remained stable in 47 patients (48%) and progressed in six patients (6%). The fibrotic stage significantly decreased, from 1.54 ± 0.86 to 1.16 ± 1.07 units. Hepatocellular carcinoma was identified in 12 patients (12.4%). The cumulative incidence of hepatocellular carcinoma in patients with progressive fibrosis was significantly higher than that in patients with regressed or stable fibrosis (P < 0.001). A Cox proportional hazards regression analysis confirmed that progressive fibrosis in sequential liver biopsies (hazard ratio [HR], 8.30; P = 0.001) and low platelet counts before treatment (HR, 8.69; P = 0.006) were significant independent factors associated with the development of hepatocellular carcinoma in patients with a sustained virological response.
Progressive fibrosis, assessed by sequential biopsies, was significantly correlated with development of hepatocellular carcinoma in patients who had achieved a sustained virological response for hepatitis C virus.
即使在丙型肝炎病毒感染治疗后获得持续病毒学应答的患者中,也会发生肝细胞癌。本研究调查了通过连续肝活检评估的纤维化变化与丙型肝炎病毒持续病毒学应答患者发生肝细胞癌之间的关系。
我们纳入了 97 例获得持续病毒学应答的患者,这些患者在治疗前进行了初次肝活检,并在初次肝活检后平均 5.8±1.9 年进行了连续肝活检。回顾性分析了与肝细胞癌相关的因素。
44 例患者(45%)的肝纤维化分期消退,47 例患者(48%)稳定,6 例患者(6%)进展。纤维化分期显著降低,从 1.54±0.86 降至 1.16±1.07 单位。12 例患者(12.4%)确诊为肝细胞癌。进展性纤维化患者的肝细胞癌累积发生率明显高于纤维化消退或稳定患者(P<0.001)。Cox 比例风险回归分析证实,连续肝活检中的进展性纤维化(风险比[HR],8.30;P=0.001)和治疗前血小板计数低(HR,8.69;P=0.006)是与持续病毒学应答患者肝细胞癌发展相关的显著独立因素。
通过连续肝活检评估的进展性纤维化与丙型肝炎病毒持续病毒学应答患者肝细胞癌的发生显著相关。